Anti-TL1A deals reach this value after Merck/Prometheus validation

TL1A has become the hottest target in gastroenterology since Merck acquired Prometheus Biosciences for $10.8B. The dual anti-inflammatory and anti-fibrotic mechanism addresses critical unmet need in Crohn's disease. Phase 2 anti-TL1A deals average $3.3B total value, while IL-23 GI deals reach $3.0B. The competitive landscape now includes 10+ clinical-stage TL1A programs from Roche, Pfizer, AbbVie, and Sanofi.

Based on analysis of 600+ biopharma licensing deals from 2020-2026